帕比司他与再放疗联合用于进展性弥漫性内生型脑桥胶质瘤：2例报告
Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases.
作者信息
Wang Zhihong J, Ge Yubin, Altinok Deniz, Poulik Janet, Sood Sandeep, Taub Jeffrey W, Edwards Holly, Kieran Mark W, Steven Miller
机构信息
Departments of *Pediatrics, Division of Pediatric Hematology Oncology †Oncology, Molecular Therapeutics Program ‡Radiology §Pathology ∥Neurosurgery, Children's Hospital of Michigan #Radiation Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI ¶Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA.
出版信息
J Pediatr Hematol Oncol. 2017 Aug;39(6):e332-e335. doi: 10.1097/MPH.0000000000000806.
Diffuse intrinsic pontine glioma (DIPG) remains a devastating disease. Panobinostat has been shown to have therapeutic efficacy both in vitro and in DIPG orthotopic xenograft models; however, clinical data in patients with DIPG are lacking. We present 2 cases of DIPG, who were treated with panobinostat at 22 to 25 mg/m/dose, 3 times weekly for 2 weeks in 3-week cycles and concomitant reirradiation after disease progression. Two episodes of asymptomatic thrombocytopenia were observed in 1 patient. Hyperacetylation of histone H4 of peripheral blood mononuclear cells was evident following treatment. In our experience, panobinostat administered with reirradiation was well tolerated at a relatively higher dose than that used in adult studies.
弥漫性脑桥内在型胶质瘤（DIPG）仍然是一种极具毁灭性的疾病。帕比司他已在体外和DIPG原位异种移植模型中显示出治疗效果；然而，DIPG患者的临床数据尚缺。我们报告2例DIPG患者，他们接受帕比司他治疗，剂量为22至25mg/m/剂量，每周3次，共2周，每3周为一个周期，疾病进展后同时进行再照射。1例患者出现2次无症状性血小板减少。治疗后外周血单个核细胞组蛋白H4的高乙酰化明显。根据我们的经验，与再照射联合使用时，帕比司他在相对高于成人研究中使用的剂量下耐受性良好。
Zotero 插件